SCHEMBL18152287

SCHEMBL18152287

CC(C)(C)OC(=O)N1CC[C@H](Oc2ccc(C(=O)O)cc2-c2ccc(F)cc2)C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.47
PIK3CD O00329 2/20 0.47
PIK3CA P42336 2/20 0.47
PIK3CB P42338 2/20 0.47
PIK3CG P48736 2/20 0.47
PDE4B Q07343 3/20 0.46
PDE4D Q08499 3/20 0.46
PDE4A P27815 2/20 0.46
PDE4C Q08493 2/20 0.46
GPR119 Q8TDV5 1/20 0.46
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
USP30 Q70CQ3 1/20 0.45
P2RY14 Q15391 1/20 0.45
BCL9 O00512 4/20 0.45
CTNNB1 P35222 4/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MMP13 P45452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18152375 1.00 TOP2A (0.47) TOP2APIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18152288 1.00 TOP2A (0.47) TOP2APIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18152348 0.92 USP30 (0.45) TOP2APDE4BPDE4DPDE4APDE4C
SCHEMBL30350445 0.91 BCL9 (0.47) TOP2APIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18152297 0.91 BCL9 (0.47) TOP2APIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18152414 0.91 BCL9 (0.47) TOP2APIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18152295 0.91 BCL9 (0.47) TOP2APIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL19404274 0.91 PIK3CD (0.48) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL30392282 0.91 PIK3CD (0.48) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL23456173 0.90 BCL9 (0.51) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542250-B2 Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-01-03 US disclosed
US-20210179583-A1 INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2021-06-17 US disclosed
WO-2017165839-A1 METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-28 WO disclosed
WO-2016168524-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542250-B2 Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction BCL9, BCL9L, BCL3 TOP2A 365/4885PIK3CD 1945/4885PIK3CA 1553/4885
US-20210179583-A1 INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION BCL9, BCL9L, BCL3 TOP2A 365/4885PIK3CD 1945/4885PIK3CA 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.